# Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-human-radiolabeled-mass-balance-studies/3a1b0e14-f87e-4c72-b198-baa24f196e9a

> FDA guidance document: Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies. Issue date: September 26, 2024. Get complete insights and analysis.

---

## Details

- Title: Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-09-26
- Comment Close Date: 2022-08-04
- Last Changed: 2024-09-27
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0113">FDA-2022-D-0113</a>

## Related Documents

- [Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-drug-interaction-studies-with-combined-oral-contraceptives-guidance-for-industry-guidance-for-industry/66dca3d2-f3c0-447f-8085-fd2e7ebd60c6)
- [Providing Over-the-Counter Monograph Submissions in Electronic Format](https://www.globalkeysolutions.net/guidances/guidance-document/providing-over-the-counter-monograph-submissions-in-electronic-format/772bd042-0dda-4d43-a221-6577f1e823b9)
- [Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance-for-industry/716f5680-73b2-4cf4-a88d-c5ade3c8aecd)